Currently, the use of bioresorbable vascular scaffolds (BRS) for the treatment of left main (LM) coronary artery disease has to be considered investigational. However, some early evidence from case reports supports the feasibility of BRS implantation in selected cases and shows good angiographic and clinical results with current-generation BRS devices. However, before the routine use of BRS for LM disease can be advocated, more data on long-term safety and efficacy and larger scaffold designs are essential.